This is an old revision of this page, as edited by Innerstream (talk | contribs) at 21:10, 24 December 2024 (new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 21:10, 24 December 2024 by Innerstream (talk | contribs) (new page)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
Other names | VNRX-5133, VNRX5133 |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C19H28BN3O5 |
Molar mass | 389.26 g·mol |
3D model (JSmol) | |
SMILES
|
Taniborbactam (development code VNRX-5133) is a pharmaceutical drug that acts as a β-lactamase inhibitor. It inhibits the function of bacterial β-lactamases which impart resistance to β-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the New Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.
Taniborbactam, in combination with cefepime, is in clinical trials for the treatment of bacterial infections, including urinary tract infection and pyelonephritis.
References
- . doi:10.1021/acs.jmedchem.9b01518.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - . doi:10.1016/S1473-3099(23)00069-5.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - . doi:10.1056/NEJMoa2304748.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - "Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight.
This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |